Overview

Chlorthalidone and HCTZ Impacts on Platelet Activation

Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
This will be a randomized, double-blinded, three-period crossover study of platelet activation and aggregation in 30 non-smoking healthy volunteers comparing chlorthalidone (CTD), hydrochlorothiazide (HCTZ), and aspirin (ASA; active control). The study hypothesis is that CTD has different effects on platelet activation and aggregation than HCTZ.
Phase:
Phase 4
Details
Lead Sponsor:
Creighton University
Collaborator:
Dialysis Clinic, Inc.
Treatments:
Aspirin
Chlorthalidone
Hydrochlorothiazide